ClinicalTrials.gg

Program

JNJ-89862175

A development code.

Its studies are led by Johnson & Johnson.

Furthest: phase 1, since Oct 30, 20251 company-led study, 1 open or runningNext primary completion: Dec 15, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson11 open or runningphase 1since Oct 30, 2025Oct 30, 2025Dec 15, 2026phase 1 · NCT07223125
  • Named in Johnson & Johnson’s own pipeline as JNJ-2175, phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 30, 2025First study: phase 1 study in Advanced-stage Solid TumorsFirst studyNCT07223125 · 360 planned · United States, France, South Korea

Ahead

  1. Dec 15, 2026Primary completion: phase 1 study in Advanced-stage Solid TumorsNCT07223125

TargetBeta

“A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors”study text, read by Claude · the study

Other programs on ENPP3

ProgramCompanyFurthest phaseStudies
Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387Johnson & Johnsonphase 11
GTX-B001rulegranular-therapeutics-limitedphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07223125Advanced-stage Solid Tumors · United States, France, South Korea1RecruitingDec 15, 2026360

How it is read

Names in the registry

  • “JNJ-89862175”, 1 entry

Codes read as this program: JNJ89862175.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.